PDCD1 and soft tissue sarcoma: The pooled analysis of phase II clinical trials investigating anti-PD-1/L1 in patients with advanced soft tissue sarcomas has identified that the ORR was 15.1% and non-progression rate was 58.5% in 384 patients treated with anti-PD-1/L1 81.